

## INTERNATIONAL TRADE COMMISSION

[Investigation No. AA1921-167 (Review)]

### Pressure Sensitive Plastic Tape From Italy

#### Determination

On the basis of the record<sup>1</sup> developed in the subject five-year review, the United States International Trade Commission determines,<sup>2</sup> pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. § 1675(c)) (the Act), that revocation of the antidumping finding on pressure sensitive plastic tape from Italy would be likely to lead to continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

#### Background

The Commission instituted this review on September 1, 1998 (63 FR 46475), and determined on December 4, 1998, that it would conduct an expedited review (63 FR 70157, December 18, 1998). The views of the Commission are contained in USITC Publication 3157 (February 1999), entitled *Pressure Sensitive Plastic Tape from Italy: Investigation No. AA1921-167 (Review)*.

By order of the Commission.

Issued: February 3, 1999.

**Donna R. Koehnke,**

*Secretary.*

[FR Doc. 99-3271 Filed 2-9-99; 8:45 am]

BILLING CODE 7020-02-P

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances; Notice of Registration

By Notice dated December 12, 1998, and published in the **Federal Register** on December 11, 1998, (63 FR 68473), Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, made application to the Drug Enforcement Administration to be registered as an importer of phenylacetone (8501) a basic class of controlled substance listed in Schedule II.

The firm plans to import the phenylacetone for the bulk manufacture of amphetamine.

<sup>1</sup> The record is defined in sec. 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR § 207.2(f)).

<sup>2</sup> Chairman Bragg and Commissioners Crawford and Askey dissenting.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Celgene Corporation to import phenylacetone is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Celgene Corporation on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: February 2, 1999.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 99-3158 Filed 2-9-99; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances; Notice of Registration

By Notice dated December 12, 1998, and published in the **Federal Register** on December 11, 1998, (63 FR 68473), Glaxo Wellcome Inc., Attn: Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon, North Carolina 27597-2309, made application to the Drug Enforcement Administration to be registered as an importer of remifentanyl (9739), a basic class of controlled substance listed in Schedule II.

The remifentanyl is being imported for the production of Ultiva dosage forms and for research and new product development.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Glaxo Wellcome Inc. to import remifentanyl is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in

effect on May 1, 1971, at this time. DEA has investigated Glaxo Wellcome Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audit of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: February 2, 1999.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 99-3159 Filed 2-9-99; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 30, 1998, Isotec Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

| Drug                                               | Schedule |
|----------------------------------------------------|----------|
| Cathinone (1235) .....                             | I        |
| Methcathinone (1237) .....                         | I        |
| N-Ethylamphetamine (1475) .....                    | I        |
| N,N-Dimethylamphetamine (1480) .....               | I        |
| Aminorex (1585) .....                              | I        |
| Methaqualone (2565) .....                          | I        |
| Lysergic acid diethylamide (7315) .....            | I        |
| Tetrahydrocannabinols (7370) .....                 | I        |
| Mescaline (7381) .....                             | I        |
| 2,5-Dimethoxyamphetamine (7396) .....              | I        |
| 3,4-Methylenedioxyamphetamine (7400) .....         | I        |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404) ..... | I        |
| 3,4-Methylenedioxymethamphetamine (7405) .....     | I        |
| 4-Methylamphetamine (7411) .....                   | I        |
| Psilocybin (7437) .....                            | I        |
| Psilocyn (7438) .....                              | I        |
| N-Ethyl-1-phenylcyclohexylamine (7455) .....       | I        |
| Dihydromorphine (9145) .....                       | I        |